---
title: "editorial no metformin diauetes"
year: 2024
month: 03
journal: "American Family Physician"
volume: "109-110"
issue: "03"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-03-editorial-no-metformin-diabetes.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial no metformin diauetes

                                                                 Editorials
                                                 Controversies in Family Medicine

                        Should Metformin Continue
                       as First-Line Pharmacotherapy
                     for Patients With Type 2 Diabetes?
No:​Other Drugs Have Stronger Evidence of Benefit                                   mortality (Table 1).5-8 One of the analyses found that adding
Henry C. Barry, MD, MS, Michigan State                                              metformin to sulfonylureas increased all-cause mortality
University, East Lansing, Michigan                                                  compared with sulfonylurea monotherapy.5 A 2023 network
Allen F. Shaughnessy, PharmD, MMedEd, Tufts                                         meta-analysis of 816 randomized trials found that met-
University School of Medicine, Boston, Massachusetts                                formin is not convincingly different than standard treat-
                                                                                    ments in decreasing mortality in patients with an average
Clinicians and patients were excited when research showed                           body mass index of 29.5 kg per m 2 or greater, with three
that metformin reduces mortality and decreases complica-                            or fewer cardiovascular risk factors, with more than three
tions associated with type 2 diabetes mellitus. However, the                        risk factors, or who are already diagnosed with cardiovas-
initial enthusiasm has been tempered by further research                            cular disease.8 Better options exist. This meta-analysis also
that has yet to support these claims and by new medication                          found that sodium-glucose cotransporter-2 inhibitors and
options with greater promise.                                                       glucagon-like peptide-1 receptor agonists are most effec-
   Metformin quickly became the cornerstone of treatment                            tive at reducing all-cause and cardiovascular mortality and
following reports from the United Kingdom Prospec-                                  other cardiac-related problems in patients with pre-existing
tive Diabetes Study (UKPDS) that stated that metformin                              cardiovascular disease. However, they were less effective in
decreased several outcomes (e.g., overall mortality, stroke),                       patients at lower risk.8
independent of its effect on serum blood glucose levels, com-                          We now have a robust database, which has evolved over
pared with dietary advice alone.1 The mortality benefit was                         the past 20 years. The medical literature comprises at least
found only in patients who were overweight.2                                        four meta-analyses and many unique randomized trials.
   The UKPDS was the first to show the benefit of medica-                           The evidence accumulated since the initial UKPDS does not
tion treatment on important clinical outcomes. However, the                         show a clear advantage of using metformin to treat patients
UKPDS has been criticized for its shortcomings.3 The study                          with type 2 diabetes.
began in 1977 with a small grant and later burgeoned into a                            As is common in medicine, guidelines have been slow
20-year study enrolling 5,102 people with newly diagnosed                           to change. The 2023 American Diabetes Association
type 2 diabetes identified throughout the United Kingdom.4                          guidelines on the treatment of type 2 diabetes continue to
The study protocol was adjusted multiple times, including                           recommend metformin as first-line therapy. Previous ver-
the addition of metformin after the trial was underway. The                         sions​of the guidelines have cited the UKPDS; however, the
study was unblinded and did not have a control group. Only                          2024 guideline released in January no longer recognizes
342 adults who were overweight received metformin.2                                 the UKPDS but also does not mention the more recent
   The results of the UKPDS have not been reproduced. Sev-                          meta-analysis.9,10
eral meta-analyses have not found metformin to be more                                 We are equally concerned about the overzealous extrap-
effective than any other comparison in decreasing clinically                        olation of research findings to include patients who differ
important outcomes such as all-cause or cardiovascular                              from the original study populations. We have already seen
                                                                                    this with metformin and caution against prematurely rec-
                                                                                    ommending the newer agents, which have been primarily
   This is one in a series of pro/con editorials discussing con-
   troversial issues in family medicine.                                            studied in patients with preexisting cardiovascular disease,
   See related editorial on page 200.
                                                                                    to all patients with type 2 diabetes.
                                                                                       Unfortunately, metformin, a safe, tolerable, inexpen-
   A collection of Editorials:​Controversies in Family Medicine
   published in AFP is available at https://​w ww.aafp.org/afp/                     sive, and easy-to-use treatment, does not offer the benefits
   pro-con.                                                                         the UKPDS initially suggested. However, sodium-glucose
   Author disclosure:​No relevant financial relationships.                          cotransporter-2 inhibitors and glucagon-like peptide-1
                                                                                    receptor agonists have demonstrated benefit, especially in

202  American
Downloaded  from Family   Physician
                 the American   Family Physician website at www.aafp.org/afp.           © 2024 American Academy Volume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                     of Family 109,
                                                                                                                                  Physicians.
                                                                                                                                       Number For 3the private,
                                                                                                                                                    ◆  March non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                                                                2024
                                                                EDITORIALS


patients with established cardiovascular disease.6 Tools                    easy to use, and affordable, the science supporting them is
are available to determine the benefits and harms (https://​                stronger, albeit in patients not representative of those we see
matchit.magicevidence.org/230125dist-diabetes1/#!/).                        in primary care. Clinicians need to exercise judgment in
Although these newer drug classes are not as well tolerated,                the care of patients:​we should follow the evidence, balance


   TABLE 1

   Comparison of Mortality Outcomes for Type 2 Diabetes Mellitus Treatments
                    Number of trials        Comparisons (subsections are            Risk ratio for met-
                    (number of              for selected comparisons with           formin outcomes
   Study            participants)           adequate data)                          (95% CI)*                    Comments

   Boussageon       13 RCTs​(13,110)        Metformin plus sulfonylureas vs.        All-cause mortality:         Included UKPDS;​data
   20125                                    sulfonylureas                           1.53 (1.02 to 2.31)          were heterogeneous,
                                                                                                                 which resolved after re-
                                                                                                                 moving UKPDS

   Madsen           32 RCTs (28,746)        Metformin plus sulfonylureas            No trial compared            Excluded UKPDS because
   2019                                     vs. metformin monotherapy or            metformin with place-        it “did not compare inter-
   (Cochrane                                other glucose-lowering                  bo or no intervention        ventions of interest”
   review)6                                 interventions

                                            Metformin plus sulfonylureas vs.        All-cause mortality:         —
                                            glucagon-like peptide-1 receptor        1.15 (0.49 to 2.67)
                                            agonists

                                            Metformin plus sulfonylureas vs.        All-cause mortality:         —
                                            dipeptidyl-peptidase-4 inhibitors       1.32 (0.76 to 2.28)
                                                                                    Cardiovascular mortal-
                                                                                    ity: 1.54 (0.63 to 3.79)

                                            Metformin plus sulfonylureas vs.        All-cause mortality:         —
                                            sodium-glucose cotransporter-2          0.96 (0.44 to 2.09)
                                            inhibitors                              Cardiovascular mortal-
                                                                                    ity: 1.22 (0.33 to 4.41)

   Gnesin          18 RCTs (10,680)         Metformin monotherapy vs. pla-          No trial compared            Included UKPDS​
   2020 (Co-                                cebo, no intervention, diet, other      metformin with place-
   chrane review)7                          hypoglycemic agents                     bo or no intervention

                                            Metformin vs. sulfonylureas             All-cause mortality:         —
                                                                                    0.99 (0.61 to 1.62)
                                                                                    Cardiovascular mortal-
                                                                                    ity: 0.50 (0.15 to 1.65)

                                            Metformin vs. thiazolidinediones        All-cause mortality:         —
                                                                                    0.88 (0.55 to 1.39)
                                                                                    Cardiovascular mortal-
                                                                                    ity: 0.71 (0.21 to 2.39)

   Shi              816 RCTs                All drug treatments for patients        All-cause mortality:         Included UKPDS
   20238            (471,038);​92 used      with type 2 diabetes, in combi-         0.84 (0.67 to 1.04)
                    metformin as            nation or as monotherapy (13            Cardiovascular mortal-
                    first-line therapy      different drug classes)                 ity: 0.95 (0.48 to 1.88)

   RCT = randomized controlled trial;​UKPDS = United Kingdom Prospective Diabetes Study.
   *—Even after pooling, the data for some comparisons were too few to estimate cardiovascular mortality.
   Information from references 5-8.




March 2024 ◆ Volume 109, Number 3                           www.aafp.org/afp                                  American Family Physician 203
                                                                 EDITORIALS


benefits and harms, weigh the economic and implementation                   3. Ewart RM. The UKPDS:​what was the question? Lancet. 1999;​353(9167):​
                                                                               1882.
costs, and change practices when better and more relevant
                                                                            4. Holman RR. Brief history of the UK Prospective Diabetes Study. Br J
data are presented.                                                            Diabetes. 2022;​22(suppl 1):​S32-S35.
                                                                            5. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of met-
 Editor’s note:​ Dr. Shaughnessy is an assistant medical                       formin efficacy in the treatment of type 2 diabetes:​a meta-analysis of
 editor for AFP.                                                               randomised controlled trials. PLoS Med. 2012;​9(4):​e1001204.
                                                                            6. Madsen KS, Kähler P, Kähler LKA, et al. Metformin and second- or third-
                                                                               generation sulphonylurea combination therapy for adults with type
Address correspondence to Henry C. Barry, MD, MS, at                           2 diabetes mellitus. Cochrane Database Syst Rev. 2019;​(4):​CD012368.
henbarry@​gmail.com. Reprints are not available from the                     7. Gnesin F, Thuesen ACB, Kähler LKA, et al. Metformin monotherapy for
authors.                                                                        adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;​
                                                                                (6):​CD012906.
References                                                                  8. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment
 1. McCormack J, Greenhalgh T. Seeing what you want to see in ran-             for type 2 diabetes:​systematic review and network meta-analysis of
    domised controlled trials:​versions and perversions of UKPDS data.         randomised controlled trials. BMJ. 2023;​381:​e074068.
    United Kingdom Prospective Diabetes Study. BMJ. 2000;​320(7251):​       9. ElSayed NA, Aleppo G, Aroda VR, et al.;​American Diabetes Association.
    1720-1723.                                                                 9. Pharmacologic approaches to glycemic treatment:​standards of care
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive            in diabetes-2023. Diabetes Care. 2023;​46(suppl 1):​S140-S157.
   blood-glucose control with metformin on complications in overweight      10. American Diabetes Association Professional Practice Committee. 9.
   patients with type 2 diabetes (UKPDS 34) [published correction appears       Pharmacologic approaches to glycemic treatment:​standards of care in
   in Lancet. 1998;​352(9139):​1558]. Lancet. 1998;​352(9131):​854-865.         diabetes-2024. Diabetes Care. 2024;​47(suppl 1):​S158-S178. ■




Rediscover Your Mojo.
And Keep It.
Physician Health &
Well-being Conference
May 6–8
Scottsdale, AZ
Register Now at aafp.org/PHWB




204 American Family Physician                                www.aafp.org/afp                                Volume 109, Number 3 ◆ March 2024
